Company registration number 14330286 (England and Wales)
THE W MEDISPA GROUP LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
THE W MEDISPA GROUP LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
THE W MEDISPA GROUP LTD
BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
227,786
40,120
Tangible assets
4
9,496
3,893
237,282
44,013
Current assets
Stocks
86,453
48,190
Debtors
5
53,137
435,087
Cash at bank and in hand
57,211
314,808
196,801
798,085
Creditors: amounts falling due within one year
6
(287,296)
(144,123)
Net current (liabilities)/assets
(90,495)
653,962
Total assets less current liabilities
146,787
697,975
Creditors: amounts falling due after more than one year
7
(515,000)
-
0
Net (liabilities)/assets
(368,213)
697,975
Capital and reserves
Called up share capital
201
173
Share premium account
1,846,239
1,228,560
Profit and loss reserves
(2,214,653)
(530,758)
Total equity
(368,213)
697,975
THE W MEDISPA GROUP LTD
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2025
31 March 2025
- 2 -

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 22 December 2025 and are signed on its behalf by:
Ms S Idicula
Director
Company registration number 14330286 (England and Wales)
THE W MEDISPA GROUP LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
1
Accounting policies
Company information

The W Medispa Group Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Washington Barn, Little Street, Sulgrave, Banbury, Northamptonshire, OX17 2SG.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

These financial statements have been prepared on the basis of going concern. The directors have a reasonable expectation that the company will remain operational for the foreseeable future. However, the company has net liabilities, and the directors are aware of certain material uncertainties that may cast doubt on its ability to continue as a going concern. Despite this, the directors are committed to providing the necessary support to ensure the company's continued operations.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Website
20% straight line
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

THE W MEDISPA GROUP LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computers
33% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

THE W MEDISPA GROUP LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 5 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
7
4
3
Intangible fixed assets
Website
£
Cost
At 1 April 2024
50,150
Additions
216,467
At 31 March 2025
266,617
Amortisation and impairment
At 1 April 2024
10,030
Amortisation charged for the year
28,801
At 31 March 2025
38,831
Carrying amount
At 31 March 2025
227,786
At 31 March 2024
40,120
THE W MEDISPA GROUP LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 6 -
4
Tangible fixed assets
Computers
£
Cost
At 1 April 2024
4,368
Additions
8,591
At 31 March 2025
12,959
Depreciation and impairment
At 1 April 2024
475
Depreciation charged in the year
2,988
At 31 March 2025
3,463
Carrying amount
At 31 March 2025
9,496
At 31 March 2024
3,893
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
23,629
-
0
Other debtors
29,508
435,087
53,137
435,087
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
183,543
90,518
Taxation and social security
18,301
42,362
Other creditors
85,452
11,243
287,296
144,123
7
Creditors: amounts falling due after more than one year
2025
2024
£
£
Loans
515,000
-
0
THE W MEDISPA GROUP LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 7 -
8
Related party transactions

During the year payments were made to Paul Spencer, a director of the company, of £29,258 (2024: £32,569) for consultancy purposes.

2025-03-312024-04-01falsefalsefalse22 December 2025CCH SoftwareCCH Accounts Production 2025.300No description of principal activityMs S IdiculaMr R M GreensheildsMrs S Lefever-BellMr P R Spence143302862024-04-012025-03-31143302862025-03-31143302862024-03-3114330286core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2025-03-3114330286core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-03-3114330286core:ComputerEquipment2025-03-3114330286core:ComputerEquipment2024-03-3114330286core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3114330286core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3114330286core:WithinOneYear2025-03-3114330286core:WithinOneYear2024-03-3114330286core:AfterOneYear2025-03-3114330286core:AfterOneYear2024-03-3114330286core:CurrentFinancialInstruments2025-03-3114330286core:CurrentFinancialInstruments2024-03-3114330286core:ShareCapital2025-03-3114330286core:ShareCapital2024-03-3114330286core:SharePremium2025-03-3114330286core:SharePremium2024-03-3114330286core:RetainedEarningsAccumulatedLosses2025-03-3114330286core:RetainedEarningsAccumulatedLosses2024-03-3114330286bus:Director12024-04-012025-03-3114330286core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3114330286core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-04-012025-03-3114330286core:ComputerEquipment2024-04-012025-03-31143302862023-04-012024-03-3114330286core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-03-3114330286core:ComputerEquipment2024-03-3114330286core:Non-currentFinancialInstruments2025-03-3114330286core:Non-currentFinancialInstruments2024-03-3114330286bus:PrivateLimitedCompanyLtd2024-04-012025-03-3114330286bus:SmallCompaniesRegimeForAccounts2024-04-012025-03-3114330286bus:FRS1022024-04-012025-03-3114330286bus:AuditExemptWithAccountantsReport2024-04-012025-03-3114330286bus:Director22024-04-012025-03-3114330286bus:Director32024-04-012025-03-3114330286bus:Director42024-04-012025-03-3114330286bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP